Thursday, Bayer shared top-line data from a phase 3 trial that tested elinzanetant in women on adjuvant endocrine therapy for ...

After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...

On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...

A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning ...

Velia Therapeutics has announced it is winding down its operations while staying loyal to the therapeutic potential of ...

With its dwindling cash reserves set to run out this month, Windtree Therapeutics had looked like it was struggling to hold ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...

“On January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and ...

Francis Medical has obtained $80 million in venture capital funding to support the development of its water vapor ablation ...

Scribe Therapeutics is slimming down its workforce by 20% as it readies its cardiometabolic pipeline for the clinic, a ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

Boston Scientific is diving into the field of intravascular lithotripsy, with a $664 million deal to pick up Bolt Medical and ...